The Development of High-throughput Identification and Heterologous Expression of Valuable Peptides/Proteins

Author(s): Chang-Jun Liu, Lei Wu, Er Meng, Dong-Yi Zhang

Journal Name: Current Proteomics

Volume 14 , Issue 1 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Peptide drugs have received more attention as potential next-generation drugs or drug leads. Such attention is primarily due to the higher target selectivities and efficiencies of peptide drugs. Moreover, peptide drugs typically have lower accumulation rates and toxicities. Although peptide drugs have advanced significantly in the 21st century, two bottlenecks (disadvantages) primarily hinder peptide drug research and development compared to small molecule drugs. One bottleneck is the identification of a valuable peptide in a complicated pool of crude products; the other bottleneck is the ability to prepare sufficient amounts of peptides for preclinical or clinical trials. This review discusses important methodologies for addressing these two bottlenecks.

Keywords: Extracellular expression, intracellular expression, in vitro screening, in vivo screening, methodology, peptide.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 06 February, 2017
Page: [13 - 23]
Pages: 11
DOI: 10.2174/1570164614666161207162711
Price: $25

Article Metrics

PDF: 20